Neuronet - Efficiently Networking European Neurodegeneration Research

Newsletter 9 - January 17, 2022

Welcome to the ninth
issue of the Neuronet newsletter! 

We hope this newsletter finds you well. As we look back at 2021, we’re proud to provide you with up-to-date insights on the Innovative Medicines Initiative’s (IMI) research efforts to tackle challenges in neurodegeneration (ND).

Beginning this year with great news, we're happy to announce that our project has received from IMI an extension of 6 months until the end of August 2022.

We were pleased to see that our third Neuronet networking event, as part of the Alzheimer Europe conference from 29 November to 1 December, was a great success. New this year was a session on the gap between preclinical and clinical research and another reporting on the NEURONET Working Groups on data sharing, ethics and privacy, regulatory interactions and sustainability. We would like to thank all chairs, presenters and participants!

Having the general public in mind, our communications team has, as always, conducted interviews with early-careers researchers, showcasing their work in IMI ND projects. This issue features authors of relevant recent publications: Anna Mallach (PHAGO), Hannah Scheiblich (PD-MitoQUANT), as well as Alison Keogh (Mobilise-D).

Furthermore, we're excited to announce that the IMI neurodegeneration programme has grown further, with the new EPND project joining our community! The goal of EPND is to become a future European infrastructure, facilitating access to biological samples and data to accelerate biomarker discovery and validation, and eventually support the development of therapeutics for neurodegenerative diseases.

Last but not least, we would like to highlight that IMI’s successor, Europe’s new partnership for health - the “Innovative Health Initiative” - will hold a launch event on 26th January!

Happy reading and enjoy!


Carlos Díaz
Neuronet Project Coordinator
Research Management Partners
Lennert Steukers
Neuronet Project Leader
Associate Director,
Clinical Scientist, Janssen Pharmaceutica NV



PHAGO: Understanding underlying Alzheimer’s disease processes

Read the interview

Mobilise-D: Exploring the usability of wearable devices for measuring activity

Read the interview

PD-MitoQUANT: Investigating Microglia to advance Parkinson’s disease research

Read the interview



HEALTH EUROPA features Neuronet interview with Carlos Díaz

In the article entitled “Neuronet: A new network for neurodegeneration research”, HEALTH EUROPA interview Project coordinator, Carlos Díaz. He tells how the Neuronet initiative advocates a collaborative approach for tackling neurodegenerative diseases.
Read more

Neuronet kicks off a workshop series aiming to identify key priorities and gaps in biomedical research

In October, Neuronet hosted the first in a series of workshops organised for the second stage of our landscape mapping exercise. These workshops aim to understand the priorities and gaps in neurodegenerative disease research, from the perspective of different stakeholders, and the first workshop involved the European Working Group of People with Dementia (EWGPWD).
Read more

Neuronet hosts an online meeting of its Data Sharing working group

On 14 October 2021, Neuronet convened an online meeting of its data sharing Working Group, moderated by Lennert Steukers (Janssen; Project Leader for Neuronet). The Neuronet Working Groups are cross-project spaces for experts in Innovative Medicines Initiative neurodegeneration projects, enabling them address common issues and priorities and identify opportunities for synergy and collaboration.
Read more

Neuronet co-hosts European Parliament Workshop on The Innovative Health Initiative: Building on success of the Innovative Medicines Initiative

On 28 September, Alzheimer Europe and Neuronet co-hosted an online European Parliament Workshop. The event was attended by 65 people, including EU policymakers, representatives from national Alzheimer’s associations, national health ministries, pharmaceutical companies, researchers and members of the European Working Group of People with Dementia.
Read more

New European initiative will build a collaborative platform for data and sample sharing, to accelerate the discovery and validation of biomarkers for neurodegenerative diseases

Maastricht, November 2, 2021 — Members of the European Platform for Neurodegenerative Diseases (EPND) announced on a venture to establish a collaborative platform for efficient sample and data sharing, leveraging and linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
Read more

The Mobilise-D Public Webinar Series starts in February 2022

The project kicks the year off with a bang, featuring a discussion about THE ALGORITHMS and Digital Mobility Outcomes (DMOs). Save the dates already now for all the webinars! The team has designed the first series of five webinars, twice a month (February to April 2022, 90 minutes each) where they will present and discuss cutting-edge thinking on mobility assessments, their technical validation approach, and examples of data and tools used..
Read more

RADAR-AD includes 100th participant in the clinical study

On 22 October, the RADAR-AD participating clinical center in Stavanger (Norway) included the 100th participant in the study! RADAR-AD participants share that they are happy to participate in the clinical study: they find the cognitive tasks challenging but also fun since they feel like a “brain training” for them.
Read more

IDEA-FAST qualification advice request submitted to the European Medicines Agency

On 27 September 2021, the Innovative Medicines Initative Consortium IDEA-FAST submitted a request for an initial CHMP (Committee for Medical Products for Human Use) qualification advice to discuss the results of the Feasibility Study and acceptability of the proposed design of the Clinical Observational Study for supporting the future EMA qualification procedure for the proposed endpoints use in clinical trials.
Read more



Introducing the Innovative Health Initiative: Europe’s new partnership for health

In the first session, IHI Executive Director Dr Pierre Meulien will present IHI and explain why they are launching a new European partnership for health. He will also describe what's new compared to the Innovative Medicines Initiative (IMI), and what will stay the same. IHI staff will then present opportunities for stakeholders to get involved in IHI, for example by applying to become a member of the IHI Science and Innovation Panel (SIP), or by becoming an expert evaluator. They will also offer a preview of the draft topics under consideration for inclusion in the first IHI call for proposals.
Read more

Neuronet sessions at the Alzheimer Europe Conference

The Neuronet programme held four parallel sessions as part of the Alzheimer Europe conference on 29 November to 1 December 2021. This involved showcasing public and patient involvement, common challenges & lessons learned, how preclinical research can have a potential impact on people’s lives and have a look into the future as well as the portfolio’s impact.
Read more

Neuronet project newsletters

Amyloid imaging to prevent Alzheimer's disease Newsletter
November 2021 (AMYPAD)
AMYPAD puts a spotlight on its recent General Assembly meeting, introduces collaborators and stresses highlights of the past quarter. This includes  two successful  PhD defenses as well as presentations at conferences.
Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement
September 2021 (Mobilise-D)
Mobilise-D celebrates the great success of its clinical validation study, puts a focus on how cross-project collaboration can increase impact, features a "In the Spotlight Series" and provides great interviews in its "Real World Stories Series".


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.

Any related content solely reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

          Newsletter 9 - January 17, 2022

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
NEURONET project · 14, rue Dicks · Luxembourg 1417 · Luxembourg

Email Marketing Powered by Mailchimp